Overview

Comparing Continuation or De-escalation of Bone Modifying Agents (BMA) in Patients Treated for Over 2 Years for Bone Metastases From Either Breast or Castration-resistant Prostate Cancer

Status:
Recruiting

Trial end date:
2024-11-01

Target enrollment:

Participant gender:

Summary

The investigators propose is to perform a pragmatic, multicenter, open-label, randomised clinical trial to demonstrate the efficacy and safety of either continuing or further de-escalating BMA after a minimum of two years of BMA treatment in patients with bone metastases from breast cancer and castration-resistant prostate cancer

Phase:

Phase 4

Details

Lead Sponsor:

Ottawa Hospital Research Institute

Treatments:

Denosumab
Pamidronate
Zoledronic Acid